Between 1906 and 1909, Dr. Samuel T. Darling described human histoplasmosis (of Darling or Darling’s disease) among three patients in the Canal Zone, Panama who had presented with severe emaciation, pancytopenia, intermittent fevers and splenomegaly – resembling kala-azar and disseminated tuberculosis, clinically . Dr. Darling demonstrated numerous small, intracellular encapsulated micro-organisms in tissue specimens of his patients and named the organism,
Humans acquire histoplasmosis through inhalation of
2. Global epidemiology
The global distribution of histoplasmosis and
Despite the global report of histoplasmosis, majority of the cases are reported from North and Latin America [6, 15, 18]. In North America, the Ohio and Mississippi river valleys and the Atlantic coastal states of Florida and New York have high rates of prior sub-clinical histoplasmosis based on histoplasmin skin tests [6, 15, 18]. Histoplasmosis in South and Central America is heavily driven by the HIV pandemic, and AIDS-associated histoplasmosis remains as common as tuberculosis in this region [19, 20, 21]. Imported and autochthonous cases of histoplasmosis have been described in Europe. Likewise in Africa, microfoci of histoplasmosis exist with reported large and small outbreaks have been attributed to histoplasmosis, but most infections are sporadic and imported cases from endemic areas have also been described [15, 22]. In review of literature of recently published data, chronic cavitary histoplasmosis is described as a common entity in endemic areas and commonly misdiagnosed as smear-negative tuberculosis .
In HIV population, globally, about half a million people get infected with
Histoplasmosis is a major killer of HIV-infected patients in South and Central America [29, 31]. In 2012, about 6710–15, 657 cases of symptomatic HIV-associated histoplasmosis were estimated in Latin America, with areas such as Central America, the northernmost part of South America, and Argentina having a prevalence above 30% and incidence >15 cases per 100 people living with HIV, resulting to about 671–9394 deaths related to histoplasmosis, compared with 5062 deaths related to tuberculosis reported in the region . In Brazil, AIDS-associated disseminated histoplasmosis had a mortality as high as 33.1% . In Guatemala, 31.2% of patients with advanced HIV had histoplasmosis .
Excluding the Indian sub-continent, 407 cases of histoplasmosis in South East Asia have been reported . Most cases (255 (63%)) were disseminated histoplasmosis and 177 (43%) cases were HIV associated . A similar study was reported from Bangladesh were 22 of the 26 cases had disseminated histoplasmosis, 4 had HIV, and 9 patients were misdiagnosed for tuberculosis . In a more recent study, around 1692 cases of histoplasmosis were reported from Asian countries; India (623 cases), China (611 cases), and Thailand (234 cases) .
Oladele and colleagues described 470 cases of histoplasmosis in Africa between 1952 and 2017 . In Nigeria, 4.4% of 750 subjects from across the country tested positive for histoplasmin skin test . In the East African region, a study from Northern Tanzania retrospectively identified 0.9% cases of probable histoplasmosis among febrile inpatients, ~66.7% of whom were HIV-infected and ~77.8% were clinically misdiagnosed as tuberculosis or bacterial pneumonia . In Uganda, 1.3% (2/151) of HIV-infected persons with suspected meningitis were serum
3. Syndromes of histoplasmosis
Following inhalation of
However in immunosuppressed individuals or individuals exposed to large inoculum, T-cell-mediated immunity may not contain the infection, as poorly circumscribed granulomas are usually formed, and progressive dissemination may occur [5, 41]. Patients become symptomatic and may require hospitalisation for antifungal treatment and supportive care occur [5, 41]. The most common cause of disseminated progressive disease is reactivation of latent pulmonary infection [17, 40].
3.2 Clinical manifestation
Histoplasmosis has varied presentation depending on the host immune status and the inoculum size. In immunocompetent individuals exposed to a low infectious inoculum, individuals are usually asymptomatic or experience a mild flu-like respiratory illness . In most cases, these cases go unnoticed unless patients are being investigated for a suspected outbreak. Among immunocomptent travellers exposed to highly infectious (large inocula) of
Individuals whose cellular immunity is compromised for number of reasons for example HIV infection, organ transplant, immunosuppressive therapy or biological therapy, i.e., anti-TNF-α drugs usually present with a disseminated form of histoplasmosis [10, 11, 43]. Disseminated histoplasmosis presents with fever, fatigue, malaise, anorexia, weight loss, and respiratory symptoms [1, 5]. Lymphadenopathy, hepato-spenomegaly, mulluscum contagiosum like skin lesions, and oral lesions are common. Shock with multi-organ failure and coagulopathy are terminal events and are commonly misdiagnosed for bacterial sepsis [1, 5].
In acute pulmonary histoplasmosis, almost all patients are asymptomatic or experience a self-limiting infection that often goes undetected. Symptoms appear in about 10% of patients, last for less than 2 weeks and are often misdiagnosed. Such patients are usually at extremes of age, having underlying co-morbidities or immunocompromised. Common symptoms suggestive of acute pulmonary histoplasmosis include non-productive cough, dyspnoea, headache, malaise, fever, chills, and chest pain that are due to mediastinal lymph node enlargement . Less common symptoms include rheumatologic complaints arthralgia, arthritis,
Chronic pulmonary histoplasmosis includes chronic cavitary pulmonary histoplasmosis and
Acute progressive disseminated histoplasmosis is rare except in extremes of age (less than 1 year old and more than 50 years old) and those with significant immunocompromise, for example, HIV patient with CD4 count <200 μ/l [11, 29, 32]. Acute progressive disseminated histoplasmosis may proceed after acute pulmonary histoplasmosis or re-activation of latent pulmonary lesion after a long period of latency. Patients with acute progressive disseminated histoplasmosis present with systemic (constitutional-fevers, weight loss, and weakness) and pulmonary symptoms. Focal or diffuse multi-organ is typical, with predilection for the reticuloendothelial system and the central nervous system. Physical examinations may reveal painful oropharyngeal ulceration, hepato-splenomegaly, and diffuse lymphadenopathy [5, 10, 17, 44].
A high index of clinical suspicion is required for timely diagnosis, given the non-specific nature of presentation of histoplasmosis. A robust history, physical examination, and tailored investigation are needed simultaneously for a definitive diagnosis. Although histopathology and culture remain the gold standard for diagnosis of histoplasmosis, advancements in technology have provided
Histopathology demonstrates the presence of caseating and non-caseating granulomas. Then the yeast is confirmed by special fungal stains, commonly, Gomori-methenamine silver, Giemsa or periodic acid-Schiff stains.
Antibody detection is done by different methods. The two standard assays are complement fixation and immunodiffusion . Immunodiffusion detects the presence of antigens C, H and M precipitin bands. The C antigen suggests cross reactivity between fungal species; H antigen indicates active infection; and M antigen shows acute, subacute or chronic infection. Complement fixation assay generates antibody titres. The sensitivity of antibody detection by immunodiffusion or complement fixation was between 60 and 70% . Immunodiffusion assay is more specific than complement fixation assay.
Polymerase Chain Reaction (PCR) assay has been widely accepted for detection of reservoirs for
Acute and subcute pulmonary histoplasmosis are usually self-limiting hence do not require therapy . But if symptoms persist for more than a month, then oral itraconazole is given for a period of 6–12 weeks . Cases of histoplasmosis-related acute respiratory distress syndrome may benefit from adjunctive corticosteroid steroid therapy.
In chronic pulmonary histoplasmosis, patients require long-term oral treatment with itraconazole for about 12–24 months or until radiological improvement on follow-up chest imaging . Relapse is common following discontinuation of antifungal treatment .
In acute progressive disseminated histoplasmosis, induction therapy with liposomal amphotericin B for 1–2 weeks (or 2–6 weeks for central nervous system histoplasmosis) followed by a step-down therapy with oral itraconazole for 12 months . Life-long oral itraconazole therapy is advised for patients with on-going immunosuppression. Liposomal amphotericin B is associated with better outcome than any other preparations of amphotericin B .
Human histoplasmosis is of global distribution, with patchy areas of high endemicity. The protean manifestations of histoplasmosis require a heightened index of clinical suspicion for early diagnosis and institution of appropriate treatment. Antigen-based diagnostics are the cornerstone for microbiological confirmation of histoplasmosis, given their high sensitivity and specificity, short-turn around time and non-invasiveness. Treatment is reserved for those with moderate to severe forms of pulmonary diseases, the immunocompromised, and those with disseminated diseases. Itraconazole singly or as a follow through treatment following amphotericin B are the basis of antifungal treatment.